Afiyet AB is a recently started diagnostics company based in Stockholm, focused on building sustainable diagnostics platforms for resource-limited and resource-rich settings alike using innovative cutting-edge nanotechnology for molecular diagnostics. The core technology is a microfluidics based LAMP platform that is at least 10x lower cost than typical PCR platforms. Other main benefits of the technology is that it does not require skilled personnel to operate the platform and you can run 20-30 samples in parallel which makes it much more cost efficient and significantly faster.

Afiyet AB started in April 2020 and the founders are Professor Aman Russom, Dr. Ines Pinto and Dr. Ruben Soares from KTH Royal Institute of Technology, Stockholm Sweden.

The startup is currently focusing on Covid-19, but the same platform can be used for a large number of infectious diseases which will be firther developed when the Covid pandemic subsides.

This Company is currently supported by KTH Innovation where startup projects receive extensive support from inhouse Business Development Coaches as well as additional support such as proof-of-concept funding, IP and legal counseling, team development, access to industry, mentor and investor networks.